121 related articles for article (PubMed ID: 38395156)
1. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells.
Wang H; Wu X; Sun Y; Liu A; He Y; Xu Z; Lu Y; Zhan C
J Control Release; 2024 Apr; 368():208-218. PubMed ID: 38395156
[TBL] [Abstract][Full Text] [Related]
2. Self-Adjuvant Effect by Manipulating the Bionano Interface of Liposome-Based Nanovaccines.
Jiang Z; Liu J; Guan J; Wang H; Ding T; Qian J; Zhan C
Nano Lett; 2021 Jun; 21(11):4744-4752. PubMed ID: 34010008
[TBL] [Abstract][Full Text] [Related]
3. Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses.
Pan L; Zhang L; Deng W; Lou J; Gao X; Lou X; Liu Y; Yao X; Sheng Y; Yan Y; Ni C; Wang M; Tian C; Wang F; Qin Z
J Control Release; 2023 May; 357():133-148. PubMed ID: 36972863
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
5. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
ACS Appl Mater Interfaces; 2022 Sep; 14(35):39858-39865. PubMed ID: 36007113
[TBL] [Abstract][Full Text] [Related]
6. A Novel Platform for Cancer Vaccines: Antigen-Selective Delivery to Splenic Marginal Zone B Cells via Repeated Injections of PEGylated Liposomes.
Shimizu T; Abu Lila AS; Kawaguchi Y; Shimazaki Y; Watanabe Y; Mima Y; Hashimoto Y; Okuhira K; Storm G; Ishima Y; Ishida T
J Immunol; 2018 Nov; 201(10):2969-2976. PubMed ID: 30333124
[TBL] [Abstract][Full Text] [Related]
7. Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses.
Wang N; Zuo Y; Wu S; Huang C; Zhang L; Zhu D
Acta Pharm Sin B; 2022 Dec; 12(12):4486-4500. PubMed ID: 36561992
[TBL] [Abstract][Full Text] [Related]
8. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
9. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
Okazaki S; Iwasaki T; Yuba E; Watarai S
J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
[TBL] [Abstract][Full Text] [Related]
11. An Immunomodulatory Zinc-Alum/Ovalbumin Nanovaccine Boosts Cancer Metalloimmunotherapy Through Erythrocyte-Assisted Cascade Immune Activation.
Zhao J; Zhang L; Li P; Liu S; Yu S; Chen Z; Zhu M; Xie S; Ling D; Li F
Adv Sci (Weinh); 2024 Feb; 11(6):e2307389. PubMed ID: 38064201
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
13. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
14. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
15. Mannose-Functionalized Biodegradable Nanoparticles Efficiently Deliver DNA Vaccine and Promote Anti-tumor Immunity.
Sun B; Zhao X; Wu Y; Cao P; Movahedi F; Liu J; Wang J; Xu ZP; Gu W
ACS Appl Mater Interfaces; 2021 Mar; 13(12):14015-14027. PubMed ID: 33751882
[TBL] [Abstract][Full Text] [Related]
16. Role of marginal zone B lymphocytes in invariant NKT cell activation.
Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
[TBL] [Abstract][Full Text] [Related]
17. Oral lymphatic delivery of alpha-galactosylceramide and ovalbumin evokes anti-cancer immunization.
Pandey P; Kim SH; Subedi L; Mujahid K; Kim Y; Cho YC; Shim JH; Kim KT; Cho SS; Choi JU; Park JW
J Control Release; 2023 Apr; 356():507-524. PubMed ID: 36907564
[TBL] [Abstract][Full Text] [Related]
18. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
Hornung RL; Longo DL; Bowersox OC; Kwak LW
J Natl Cancer Inst; 1995 Sep; 87(17):1289-96. PubMed ID: 7544833
[TBL] [Abstract][Full Text] [Related]
19. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
[TBL] [Abstract][Full Text] [Related]
20. IL-7 is required for the development of the intrinsic function of marginal zone B cells and the marginal zone microenvironment.
Willems L; Li S; Rutgeerts O; Lenaerts C; Waer M; Billiau AD
J Immunol; 2011 Oct; 187(7):3587-94. PubMed ID: 21873520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
